Shawna Gvazdauskas Appointed as Executive Vice President at Common Sensing
CAMBRIDGE, Mass., Dec. 6, 2018 /PRNewswire/ -- Common Sensing, developer and manufacturer of the Gocap smart injectable medicine monitor, announced that Shawna Gvazdauskas has been appointed Executive Vice President of Commercial Development.
Ms. Gvazdauskas has thirty years of commercial leadership experience in consumer, pharmaceutical and medical device industries. She has held director and executive level commercial positions at Johnson & Johnson, Sanofi, TheraSense and Insulet. Ms. Gvazdauskas has a history of building and leading successful teams in big pharma as well as early stage companies. She has led commercial efforts through the $1.2 billion acquisition of Therasense's FreeStyle blood glucose monitoring products by Abbott Diabetes as well as Insulet's $120 million IPO.
"I was introduced to the Common Sensing team five years ago and was instrumental in gaining an early investment by Sanofi Genzyme Bioventures. As the Sanofi Board Advisor to Common Sensing, it was apparent that the Gocap technology is very promising. It is exciting to now join the team to provide guidance for commercialization of a device and app designed to help patients better understand how they dose self-injected medicine. Real patients are now observing real data through Gocap clinical studies," said Ms. Gvazdauskas.
Chief Executive Officer Kevin Schmid said, "Shawna's eagerness to join the team is an indication of her confidence in Common Sensing's very bright future. She has vast experience in diabetes as well as medical device commercialization and will be focused on developing our go-to-market plan as well as building a best-in-class commercial leadership team."
A series of exciting accomplishments such as Series A financing, a development agreement with Haselmeier and a development partnership with Flex for the CS Gen 2 Gocap commercial platform are important milestones for the commercialization of Gocap.
Shawna Gvazdauskas – LinkedIn
About Common Sensing
Common Sensing develops and manufactures data-driven hardware and software solutions for people using injectable medicine. Founded in 2012, Common Sensing has assembled a team of talented designers and engineers to develop Gocap™, the first smart cap that turns existing injector pens into smart injectors. Gocap connects insulin, GLP-1, fertility hormone, and human growth hormone injector pens to the cloud to improve outcomes and make everyday treatment more convenient. Based in Cambridge, MA, Common Sensing's investors include Waterline Ventures, Qualcomm Ventures, Sanofi, Haselmeier, Philips, and New World Health.
Media Contact
Kelly Pavao
[email protected]
SOURCE Common Sensing
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article